FDA Draft Guidance 2026: Preparing Container Closure Systems And Device Constituent Parts For Biosimilar And Interchangeable Biosimilar Combination Products

How FDA Draft Guidance, Container Closure Systems, Device Constituent Parts, Human Factors Engineering, Comparative Studies, Quality by Design, and Regulatory Strategy Are Supporting Successful Biosimilar Combination Product Development

The U.S. Food and Drug Administration (FDA) has issued new draft guidance to assist sponsors developing biosimilar and interchangeable biosimilar combination products under section 351(k) of the Public Health Service (PHS) Act. The guidance focuses on the development, evaluation, and regulatory expectations for container closure systems (CCS) and device constituent parts (DCPs) used in products such as prefilled syringes, autoinjectors, pen injectors, and other drug-device combination products.

As biosimilars continue expanding across therapeutic areas, sponsors should ensure that device design, usability, manufacturing controls, and regulatory documentation align with FDA expectations while maintaining similarity to the reference product. Early planning for device development, comparative assessments, risk management, and regulatory strategy can help reduce review timelines and support successful market authorization.

Why FDA's Draft Guidance Is a Strategic Priority

The U.S. biosimilars market continues to grow rapidly, driven by:

• Increasing biologic patent expirations 
• Growing demand for lower-cost biologic therapies 
• Expansion of interchangeable biosimilars 
• Rising adoption of self-administered injectable products 
• Increased use of autoinjectors and prefilled syringes 
• Continued FDA support for biosimilar competition 
• Advances in drug-device combination technologies 

FDA emphasizes that sponsors should carefully evaluate the presentation of the proposed biosimilar relative to the reference product.

According to FDA:

"The proposed presentation cannot result in a condition of use that has not been previously approved for the reference product or a dosage form, strength, or route of administration that is not the same as the reference product."

Failure to adequately address these considerations may result in:

• Regulatory deficiencies 
• Additional FDA information requests 
• Extended review timelines 
• Human factors concern 
• Device performance questions 
• Comparative study deficiencies 
• Manufacturing delays 
• Approval postponements 
• Increased development costs 
• Market launch delays 

Regulatory readiness has become a competitive advantage for sponsors developing biosimilar combination products.

Executive Overview

Successful development of biosimilar combination products requires more than demonstrating bio similarity.

Organizations should establish an integrated development strategy incorporating:

• FDA regulatory compliance 
• Container closure system development 
• Device constituent part evaluation 
• Human factors engineering 
• Comparative analytical studies 
• Design verification and validation 
• Risk management 
• Quality by Design (QbD) 
• Manufacturing readiness 
• Labeling compliance 
• Lifecycle management 
• Post-market surveillance 

Companies adopting these capabilities improve regulatory confidence while accelerating commercialization.

Understanding FDA's Draft Guidance

FDA's draft guidance provides recommendations for sponsors development:

• Biosimilar combination products
• Interchangeable biosimilars 
• Prefilled syringes 
• Autoinjectors 
• Pen injectors 
• On-body injectors 
• Drug-device combination products 

The guidance explains how sponsors should evaluate whether differences in container closure systems or device constituent parts may affect:

• Safety 
• Effectiveness 
• User interface 
• Product quality 
• Clinical performance 
• Patient usability 
• Product presentation 

FDA continues promoting a science- and risk-based approach for combination product development.

Key Regulatory Authorities

Why Presentation Matters

FDA emphasizes that proposed biosimilar products should maintain consistency with the reference product regarding:

• Condition of use 
• Dosage form 
• Route of administration 
• Strength 
• Clinical use 
• Intended patient population 
• Administration process 

Changes that introduce a new clinical use or alter the approved presentation may not be appropriate under the biosimilar pathway.

Products Covered by Guidance

The draft guidance may apply to:

1. Prefilled Syringes

Drug products are supplied in ready-to-use syringe presentations.

2. Autoinjectors

Single-use or reusable injection devices designed for patient self-administration.

3. Pen Injectors

Injection pens delivering accurate doses for chronic therapies.

4. On-Body Delivery Systems

Wearable drug delivery devices.

5. Other Drug-Device Combination Products

Products integrating biologics with delivery devices.

Core Development Requirements

Successful biosimilar combination product development generally includes:

• Comparative analytical studies 
• Device engineering documentation 
• Container closure assessments 
• Human factors evaluation 
• Risk management file 
• Design verification 
• Design validation 
• Stability studies 
• Compatibility testing 
• Performance testing 
• Labeling assessment 
• Manufacturing controls 

Container Closure System Development

FDA recommends sponsors evaluate:

• Material compatibility 
• Extractables and leachables 
• Sterility assurance 
• Container integrity 
• Product stability 
• Drug-device compatibility 
• Functional performance 
• Shelf-life 
• Packaging configuration 
• Manufacturing consistency 

Comprehensive container closure assessments support product quality throughout the lifecycle.

Device Constituent Part Evaluation

Sponsors should evaluate:

• Device functionality 
• Mechanical performance 
• Dose accuracy 
• Injection force 
• Reliability 
• Durability 
• Ease of use 
• User interface 
• Design controls 
• Manufacturing reproducibility 

Device performance should support safe and effective administration.

Human Factors Engineering

FDA places significant emphasis on usability.

Sponsors should conduct:

• User needs analysis 
• Task analysis 
• Formative studies 
• Summative human factors validation 
• Use error assessment 
• Risk analysis 
• Patient usability evaluation 
• Healthcare professional evaluation 

Human factors data help demonstrate that users can safely administer the product.

Comparative Assessment Strategy

Comparisons between the proposed product and the reference product may include:

• Device characteristics 
• Functional performance 
• User interface 
• Administration process 
• Container closure design 
• Labeling 
• Packaging 
• Instructions for use 
• Risk profile 

Scientific justification supports regulatory decision-making.

Quality by Design (QbD)

Sponsors should establish robust quality systems addressing:

• Critical Quality Attributes (CQAs) 
• Critical Process Parameters (CPPs) 
• Design space 
• Process validation 
• Risk assessment 
• Change management 
• Continuous improvement 
• Lifecycle quality management 

QbD strengthens manufacturing consistency and product reliability.

Manufacturing Readiness

Organizations should demonstrate:

• GMP compliance 
• Process validation 
• Equipment qualification 
• Supplier qualification 
• Component control 
• Sterile manufacturing capability 
• Batch consistency 
• Quality Management System (QMS)
• CAPA effectiveness 
• Data integrity 

Manufacturing readiness supports inspection success and regulatory confidence.

Development Process

Typical development stages include:

1. Regulatory strategy 
2. Reference product assessment 
3. Development 
4. Container closure evaluation 
5. Comparative testing 
6. Human factors studies 
7. Manufacturing validation 
8. Regulatory submission 
9. FDA review 
10. Product approval 

Development Timeline Overview

Labeling Considerations

FDA expects labeling to remain consistent with the approved reference product where appropriate.

Sponsors should evaluate:

• Instructions for use 
• Device operation 
• Warnings 
• Precautions 
• Administration instructions 
• Storage conditions 
• Disposal instructions 
• Patient information 

Clear labeling supports safe product use.

Risk Management

Organizations should implement comprehensive risk management covering:

• Design risks 
• Device failures 
• User errors 
• Manufacturing risks 
• Sterility risks 
• Packaging risks 
• Supply chain risks 
• Post-market monitoring 

Risk management should continue throughout the product lifecycle.

Lifecycle Management

Following approval, companies should manage:

• Device modifications 
• Manufacturing changes 
• Packaging updates 
• Label revisions 
• Complaint investigations 
• CAPA activities 
• Stability monitoring 
• Regulatory submissions 
• Post-market surveillance 

Strong lifecycle management supports ongoing compliance.

Regulatory Intelligence

Sponsors should continuously monitor:

• FDA draft guidance 
• Final guidance updates 
• Combination product policies 
• Biosimilar approvals 
• Human factors guidance 
• GMP updates 
• Quality regulations 
• Industry best practices 

Regulatory intelligence enables proactive compliance planning.

Digital Transformation

FDA continues encouraging:

• Electronic submissions 
• eCTD implementation 
• Digital quality documentation 
• Electronic design history files
• Risk-based review 
• Digital lifecycle management 

Digital readiness improves submission efficiency.

Common Challenges

Organizations frequently encounter:

• Device design complexity 
• Human factors deficiencies 
• Comparative testing challenges 
• Manufacturing variability 
• Container compatibility issues 
• Documentation gaps 
• Regulatory uncertainty 
• Labeling revisions 
• Resource constraints 

Readiness Assessment

Best Practices

Organizations should:

• Develop regulatory strategy early 
• Align product presentation with reference product 
• Conduct comprehensive comparative studies 
• Strengthening human factors engineering 
• Validate container closure performance 
• Implement robust QMS 
• Maintain design documentation 
• Monitor FDA guidance updates 
• Strengthen cross-functional collaboration 

Common Mistakes

Avoid:

• Late device planning 
• Inadequate comparative data 
• Weak human factors evaluation 
• Poor documentation 
• Insufficient risk management 
• Manufacturing readiness gaps 
• Inconsistent labeling 
• Delayed FDA responses 

Regulatory Readiness Roadmap

Future Trends

Emerging developments include:

• Greater adoption of interchangeable biosimilars 
• Advanced autoinjector technologies 
• Digital health integration 
• AI-assisted regulatory review 
• Expanded human factors expectations 
• Risk-based device assessments 
• Increased eCTD submissions 
• Stronger lifecycle management 
• Enhanced post-market surveillance 
• Greater regulatory harmonization 

Business Benefits

Frequently Asked Questions

1. What is the purpose of the FDA draft guidance?

It provides recommendations for developing container closure systems and device constituent parts for biosimilar and interchangeable biosimilar combination products.

2. Which products are covered?

Products such as prefilled syringes, autoinjectors, pen injectors, and other drug-device combination products.

3. Why is product presentation important?

The proposed presentation should not introduce a new condition of use, dosage form, strength, or route of administration compared with the reference product.

4. Does FDA require comparative device evaluations?

Yes. Comparative assessments help demonstrate that differences do not adversely affect safety, effectiveness, or usability.

5. Are human factors testing important?

Yes. Human factors engineering is essential for demonstrating safe and effective product use.

6. What are common regulatory challenges?

Device design, comparative testing, human factors validation, documentation quality, and manufacturing readiness.

7. Why is container closure evaluation important?

It helps ensure product quality, sterility, stability, and compatibility throughout the product lifecycle.

8. How can sponsors accelerate approvals?

By planning early, maintaining robust documentation, conducting comprehensive comparative studies, and aligning closely with FDA expectations.

9. What happens after approval?

Sponsors should manage lifecycle changes, labeling updates, manufacturing modifications, complaints, and post-market surveillance.

10. How can Maven Regulatory Solutions help?

Maven supports:

• FDA regulatory strategy 
• Biosimilar regulatory consulting 
• Combination product development support 
• Container closure system assessments 
• Device constituent part documentation 
• Human factors readiness 
• GMP compliance 
• eCTD dossier preparation 
• Regulatory intelligence 
• Lifecycle management 

Conclusion

FDA's draft guidance reinforces the importance of a comprehensive, science-based approach to developing biosimilar and interchangeable biosimilar combination products. Sponsors should integrate regulatory strategy, container closure system design, device constituent part evaluation, human factors engineering, quality management, and lifecycle planning early in development to minimize regulatory risk and support efficient FDA review. Organizations that proactively align with FDA expectations will be better positioned to accelerate approvals, enhance product quality, and achieve successful commercialization.

Why Choose Maven Regulatory Solutions?

Maven Regulatory Solutions provides end-to-end regulatory support for biosimilar and combination product developers. Our expertise includes FDA regulatory strategy, biosimilar development consulting, container closure system evaluations, device constituent part documentation, human factors readiness, GMP compliance, eCTD dossier preparation, regulatory intelligence, lifecycle management, and post-approval support. We help organizations confidently navigate evolving FDA requirements while accelerating market access and maintaining global regulatory compliance.